Molecular signatures of lung cancer: Defining new diagnostic and therapeutic paradigms

Molecular Diagnosis and Therapy

Volumn 16, Issue 1, 2012, Pages 1-6

  Balko, Justin M ^a   Arteaga, Carlos L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; MESSENGER RNA; MICRORNA; NAVELBINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CHEMOSENSITIVITY; CLINICAL LABORATORY; DNA DAMAGE; ENZYME ACTIVITY; EXCISION REPAIR; GENE EXPRESSION; HEALTH ECONOMICS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MARKER GENE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR DIAGNOSIS; MOLECULAR SIGNATURE; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REIMBURSEMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; HUMANS; LUNG NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857586335     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11597430     Document Type: Review

References (47)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011 Jul-Aug; 61 (4): 212-36
2. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 2010 Apr 7; 102 (7): 464-74
3. Carrola J, Rocha CM, Barros AS, et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res 2011 Jan 7; 10 (1): 221-30
4. Rocha CM, Barros AS, Gil AM, et al. Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res 2010 Jan; 9 (1): 319-32
5. Rocha CM, Carrola J, Barros AS, et al. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of blood plasma. J Proteome Res 2011 Aug 5; 10 (9): 4314-24
6. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002 Aug; 8 (8): 816-24
7. Boutros PC, Lau SK, Pintilie M, et al. Prognostic gene signatures for nonsmall- cell lung cancer. Proc Natl Acad Sci U S A 2009 Feb 24; 106 (8): 2824-8
8. Chen HY, Yu SL, Chen CH, et al.Afive-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007 Jan 4; 356 (1): 11-20
9. Guo L,MaY, Ward R, et al. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res 2006 Jun 1; 12 (11 Pt 1): 3344-54
10. Kadara H, Behrens C, Yuan P, et al. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res 2011 Mar 15; 17 (6): 1490-501
11. Larsen JE, Pavey SJ, Passmore LH, et al. Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis 2007 Mar; 28 (3): 760-6 (Pubitemid 46523374)
12. Larsen JE, Pavey SJ, Passmore LH, et al. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 2007 May 15; 13 (10): 2946-54 (Pubitemid 46849569)
13. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for earlystage non small-cell lung cancer. J Clin Oncol 2007 Dec 10; 25 (35): 5562-9
14. Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006 Dec; 3 (12): e467
15. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006 Aug 1; 66 (15): 7466-72 (Pubitemid 44289200)
16. Raz DJ, Ray MR, Kim JY, et al. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res 2008 Sep 1; 14 (17): 5565-70
17. Roepman P, Jassem J, Smit EF, et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 2009 Jan 1; 15 (1): 284-90
18. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008 Aug; 14 (8): 822-7
19. Skrzypski M, Jassem E, Taron M, et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 2008 Aug 1; 14 (15): 4794-9
20. Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 2008 Feb 20; 26 (6): 877-83 (Pubitemid 351398079)
21. Tomida S, Koshikawa K, Yatabe Y, et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 2004 Jul 8; 23 (31): 5360-70 (Pubitemid 39005811)
22. Zhu CQ, Ding K, Strumpf D, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010 Oct 10; 28 (29): 4417-24
23. Nesbitt JC, Putnam Jr JB, Walsh GL, et al. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 1995 Aug; 60 (2): 466-72
24. National Comprehensive Cancer Network. NCCN practice guidelines in oncology: small cell lung cancer [online]. Available from URL: http://www.nccn. org/professionals/physician-gls/pdf/sclc.pdf [Accessed 2012 Jan 20]
25. National Comprehensive Cancer Network. NCCN practice guidelines in oncology: non-small cell lung cancer [online]. Available from URL: http://www. nccn.org/professionals/physician-gls/pdf/nscl.pdf [Accessed 2012 Jan 20]
26. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 2005 Jun 23; 352 (25): 2589-97
27. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004 Jan 22; 350 (4): 351-60 (Pubitemid 38101630)
28. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008 Jul 20; 26 (21): 3552-9
29. Kratz JR, Jablons DM. Genomic prognostic models in early-stage lung cancer. Clin Lung Cancer 2009 May; 10 (3): 151-7
30. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 Dec 30; 351 (27): 2817-26 (Pubitemid 40051905)
31. Keller A, Leidinger P, Gislefoss R, et al. Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol 2011 May 1; 8 (3): 506-16
32. Bianchi F, Nicassio F, Marzi M, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011 Aug; 3 (8): 495-503
33. Azuma K, Okamoto I, Kawahara A, et al. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation- specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol 2012 Jan; 7 (1): 122-7
34. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010 Jun 24; 362 (25): 2380-8
35. Kim DW, Lee SH, Lee JS, et al. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer 2011 Jan; 71 (1): 65-9
36. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010 Feb 10; 28 (5): 744-52
37. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009 Sep 3; 361 (10): 958-67
38. Balko JM, Potti A, Saunders C, et al. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics 2006; 7: 289
39. Coldren CD, Helfrich BA, Witta SE, et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 2006 Aug; 4 (8): 521-8 (Pubitemid 44341362)
40. Balko JM, Black EP. A gene expression predictor of response to EGFRtargeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer 2009; 9: 145
41. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007 Jun 6; 99 (11): 838-46
42. Amann JM, Lee JW, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 2010 Feb; 5 (2): 169-78
43. Jordheim LP, Seve P, Tredan O, et al. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 2011 Jul; 12 (7): 693-702
44. Olaussen KA, Dunant A, Fouret P, et al. DNArepair by ERCC1 in non-smallcell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006 Sep 7; 355 (10): 983-91 (Pubitemid 44343542)
45. Simon GR, Schell MJ, Begum M, et al. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. Epub 2011 Oct 25
46. Potti A, Dressman HK, Bild A, et al. Retraction: genomic signatures to guide the use of chemotherapeutics. Nat Med 2011 Jan; 17 (1): 135
47. Potti A, Mukherjee S, Petersen R, et al. Retraction: a genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2011 Mar 24; 364 (12): 1176